Exicure (Exicure) FCF Margin % : 0.00% (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Exicure FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Exicure's Free Cash Flow for the three months ended in Jun. 2023 was $-4.81 Mil. Exicure's Revenue for the three months ended in Jun. 2023 was $0.00 Mil. Therefore, Exicure's FCF Margin % for the quarter that ended in Jun. 2023 was 0.00%.

As of today, Exicure's current FCF Yield % is -525.57%.

The historical rank and industry rank for Exicure's FCF Margin % or its related term are showing as below:

XCUR' s FCF Margin % Range Over the Past 10 Years
Min: -16594.07 Med: -213.14 Max: 7409.32
Current: -92.28

During the past 7 years, the highest FCF Margin % of Exicure was 7409.32%. The lowest was -16594.07%. And the median was -213.14%.

XCUR's FCF Margin % is ranked better than
55.1% of 1040 companies
in the Biotechnology industry
Industry Median: -141.08 vs XCUR: -92.28

Exicure FCF Margin % Historical Data

The historical data trend for Exicure's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exicure FCF Margin % Chart

Exicure Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

FCF Margin %

Get a 7-Day Free Trial

-16,594.07

18.13

-255.47

7,409.32

-123.74

Exicure Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
FCF Margin %	Get a 7-Day Free Trial															-367.54	-324.80	-33.42	-	-

Competitive Comparison of Exicure's FCF Margin %

For the Biotechnology subindustry, Exicure's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Exicure's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exicure's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Exicure's FCF Margin % falls into.

Exicure FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Exicure's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-35.668	/	28.826
	=	-123.74 %

Exicure's FCF Margin for the quarter that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-4.811	/	0
	=	%

Exicure FCF Margin % Related Terms

Thank you for viewing the detailed overview of Exicure's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Exicure (Exicure) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exicure Inc (NAS:XCUR) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

2H0A:Germany 2H0A:Germany

Address

2430 N. Halsted Street, Suite 410, Chicago, IL, USA, 60614

Website

https://www.exicuretx.com

Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.

Executives

Minhee Eom	director	2430 N. HALSTED ST., CHICAGO IL 60614
Dongho Lee	director	2430 N. HALSTED ST., CHICAGO IL 60614
Hyuk Joon Ko	director	2430 N. HALSTED ST., CHICAGO IL 60614
Hojoon Lee	director	2430 N. HALSTED ST., CHICAGO IL 60614
Dgp Co., Ltd.	10 percent owner	23, GEURINTEKEU-RO, YEONGGWANG-EUP, YEONGGWANG-GUN, JEOLLANAM-DO M5 57024
Jung Sang Kim	director, officer: Chief Executive Officer, CFO	46-31 CHEONGRO 3 GIL, GEUMSUNG-MYEON, UEISUNG-GUN, GYEONGSANGBUK-DO M5 37357
Josh Miller	director, officer: Chief Executive Officer, CFO	2430 N. HALSTED ST., CHICAGO IL 60614
Jiyoung Hwang	director	C/O EXICURE, INC., 2430 N. HALSTED ST., CHICAGO IL 60614
Cheolho Jo	director	2430 N. HALSTED ST., CHICAGO IL 60614
Seung Soo Shin	director	2430 N. HALSTED ST., CHICAGO IL 60614
Hyukku Lee	director	2430 N. HALSTED ST., CHICAGO IL 60614
Sung Uh Kang Paul	director	2430 N. HALSTED ST., CHICAGO IL 60614
Changil Ahn	director	2430 N. HALSTED ST., CHICAGO IL 60614
Cbi Usa, Inc.	10 percent owner	3000 WESTERN AVENUE, SUITE 400, SEATTLE WA 98121
Bali Muralidhar	director	C/O EXICURE, INC., 8045 LAMON AVENUE, SUITE 410, SKOKIE IL 60077